Tevogen Bio Holdings Inc. cash flow to debt ratio of -397.50% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Tevogen Bio Holdings Inc.'s free cash flow has decreased 3.29% from $-12.00M last year to $-12.39M, signaling decreasing performance

Tevogen Bio Holdings Inc.'s debt to equity ratio is -0.31, signaling that the company spent its equity and risk bankruptcy.

Tevogen Bio Holdings Inc.'s debt to equity ratio is -0.31, signaling that the company spent its equity and risk bankruptcy.

Tevogen Bio Holdings Inc. has negative EBITDA, making leverage ratio unreliable

Tevogen Bio Holdings Inc.'s interest coverage ratio is -212.10, which means that the company struggles to meet interest obligations, signaling financial risk.

Tevogen Bio Holdings Inc. has insufficient data to evaluate this check.

Tevogen Bio Holdings Inc.'s short-term liabilities of $7.07M exceed its short-term assets of $1.54M, signaling financial risk

Tevogen Bio Holdings Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Tevogen Bio Holdings Inc.'s return on equity of 241.39%, is higher than 15.00%, indicating good performance

Tevogen Bio Holdings Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Tevogen Bio Holdings Inc. has insufficient public price history to evaluate earnings stability.

Tevogen Bio Holdings Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Tevogen Bio Holdings Inc. has negative free cash flow, indicating cash burn

Tevogen Bio Holdings Inc.'s yearly earnings has decreased 159.78% since last year from $-10.11M to $-26.28M, signaling decreasing performance

Tevogen Bio Holdings Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC 5.74K% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.

Tevogen Bio Holdings Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Tevogen Bio Holdings Inc. had revenue growth in 4 out of 5 years, indicating consistent revenue performance

Tevogen Bio Holdings Inc. has insufficient public price history to evaluate ROE consistency.

Tevogen Bio Holdings Inc. has insufficient data to evaluate this check.

Tevogen Bio Holdings Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Tevogen Bio Holdings Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Tevogen Bio Holdings Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Tevogen Bio Holdings Inc. has insufficient data to evaluate this check.

Tevogen Bio Holdings Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Tevogen Bio Holdings Inc. has negative shareholder equity; price-to-book is not meaningful and the check fails

Tevogen Bio Holdings Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue